Evidence map›Paper›PMID 34438104›Full record

SynthesisThe journal of allergy and clinical immunology. In practice2022

Peanut Can Be Used as a Reference Allergen for Hazard Characterization in Food Allergen Risk Management: A Rapid Evidence Assessment and Meta-Analysis.

Paul J Turner, Nandinee Patel, Barbara K Ballmer-Weber, Joe L Baumert, W Marty Blom, Simon Brooke-Taylor, Helen Brough, Dianne E Campbell, Hongbing Chen, R Sharon Chinthrajah and 20 more

Open access · hybridAbstract readMeta-Analysis
In one paragraph

Synthesis in The journal of allergy and clinical immunology. In practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 13 countries.

Paul J TurnerNational Heart & Lung Institute, Imperial College London, London, United Kingdom. Electronic address: p.turner@imperial.ac.uk.
Nandinee PatelNational Heart & Lung Institute, Imperial College London, London, United Kingdom.
Barbara K Ballmer-WeberAllergy Unit, Department of Dermatology, University of Zürich, Zürich, Switzerland; Clinic for Dermatology and Allergology, Kantonsspital St Gallen, St Gallen, Switzerland.
Joe L BaumertFood Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Neb.
W Marty BlomNetherlands Organisation for Applied Scientific Research TNO, Utrecht, the Netherlands.
Simon Brooke-TaylorBrooke-Taylor & Co Pty Ltd, Milawa, Vic, Australia.
Helen BroughChildren's Allergy Service, Evelina Children's Hospital, Guy's and St. Thomas' NHS Foundation Hospital, London, United Kingdom; Department of Paediatric Allergy, King's College London, London, United Kingdom.
Dianne E CampbellDepartment of Allergy and Immunology, the Children's Hospital at Westmead, Westmead, NSW, Australia; DBV Technologies, Montrouge, France.
Hongbing ChenState Key Laboratory of Food Science and Technology, Sino-German Joint Research Institute, Nanchang University, Nanchang, China.
R Sharon ChinthrajahSean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, Calif.
René W R CrevelRené Crevel Consulting Limited, Bedford, United Kingdom.
Anthony E J DuboisGRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Motohiro EbisawaClinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan.
Arnon ElizurInstitute of Allergy, Immunology and Pediatric Pulmonology, Yitzhak Shamir Medical Center, Zerifin, Israel; Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jennifer D GerdtsFood Allergy Canada, Toronto, ON, Canada.
M Hazel GowlandAllergy Action, St Albans, United Kingdom.
Geert F HoubenNetherlands Organisation for Applied Scientific Research TNO, Utrecht, the Netherlands.
Jonathan O B HourihaneDepartment of Paediatrics, Royal College of Surgeons in Ireland and Children's Health Ireland Temple St Hospital, Dublin, Ireland.
André C KnulstDepartment Dermatology/Allergology and Center for Translational Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Sébastien La VieilleFood Directorate, Health Canada, Ottawa, ON, Canada.
María Cristina LópezFood Engineering Department, San Martín National University, Buenos Aires, Argentina.
E N Clare MillsDivision of Infection, Immunity and Respiratory Medicine, Manchester Institute of Biotechnology, University of Manchester, Manchester, United Kingdom.
Gustavo A PolentaInstituto Nacional de Tecnología Agropecuaria (INTA), Instituto Tecnología de Alimentos, Buenos Aires, Argentina.
Natasha PuringtonDepartment of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, Calif.
Maria SaidAllergy & Anaphylaxis Australia, Castle Hill, NSW, Australia.
Hugh A SampsonDBV Technologies, Montrouge, France; Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.
Sabine SchnadtDeutscher Allergie- und Asthmabund (DAAB), Mönchengladbach, Germany.
Eva SödergrenLivsmedelsverket (Swedish Food Agency), Uppsala, Sweden; ThermoFisher Scientific, Uppsala, Sweden.
Stephen L TaylorFood Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Neb.
Benjamin C RemingtonFood Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Neb; Remington Consulting Group BV, Utrecht, the Netherlands.
University of Nebraska–Lincoln · USImperial College London · GBNetherlands Organisation for Applied Scientific Research · NLStanford University · USAllerGen · CAAllergy Action · GBChildren's Hospital at Westmead · AUDBV Technologies (France) · FRGuy's and St Thomas' NHS Foundation Trust · GBHealth Canada · CAKantonsspital St. Gallen · CHNational Institute of Industrial Technology · ARNational Sagamihara Hospital · JPNational University of General San Martín · ARRoyal College of Surgeons in Ireland · IEState Key Laboratory of Food Science and Technology · CNTel Aviv University · ILThermo Fisher Scientific (Sweden) · SEUniversity Medical Center Groningen · NLUniversity of Manchester · GB

Funding

Department of HealthMedical Research Council MR/K010468/1
6 · The paper itself

Abstract

Regional and national legislation mandates the disclosure of "priority" allergens when present as an ingredient in foods, but this does not extend to the unintended presence of allergens due to shared production facilities. This has resulted in a proliferation of precautionary allergen ("may contain") labels (PAL) that are frequently ignored by food-allergic consumers. Attempts have been made to improve allergen risk management to better inform the use of PAL, but a lack of consensus has led to variety of regulatory approaches and nonuniformity in the use of PAL by food businesses. One potential solution would be to establish internationally agreed "reference doses," below which no PAL would be needed. However, if reference doses are to be used to inform the need for PAL, then it is essential to characterize the hazard associated with these low-level exposures. For peanut, there are now published data relating to over 3000 double-blind, placebo-controlled challenges in allergic individuals, but a similar level of evidence is lacking for other priority allergens. We present the results of a rapid evidence assessment and meta-analysis for the risk of anaphylaxis to a low-level allergen exposure for priority allergens. On the basis of this analysis, we propose that peanut can and should be considered an exemplar allergen for the hazard characterization at a low-level allergen exposure.

Indexed as

AnaphylaxisFood HypersensitivityAllergensArachisFood LabelingHumansRandomized Controlled Trials as TopicRisk AssessmentAllergensAnaphylaxisEliciting doseFood allergyPrecautionary allergen labelingReference doseThreshold

Identifiers

PMID34438104
PMCPMC8790324
OpenAlexW3195201330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.